Search results for "Thromboprophylaxis"
Model for COVID-19 triage, updated guidelines for inpatients, negative trial of ivermectin
An electronic health record tool used nine variables to predict which inpatients with COVID-19 would deteriorate. Two societies updated their guidelines on inpatient thromboprophylaxis and remdesivir use. A trial found that ivermectin had no effect on disease progression or mortality.
https://acphospitalist.acponline.org/archives/2022/02/23/free/model-for-covid-19-triage-updated-guidelines-for-inpatients.htm
23 Feb 2022
DOACs better than heparin for periop thromboprophylaxis, review finds
The systematic review and network meta-analysis found lower rates of symptomatic venous thromboembolism in surgical patients given direct oral anticoagulants (DOACs) versus the standard dose of low-molecular-weight heparin, without a significant increase in bleeding.
https://acphospitalist.acponline.org/archives/2022/03/16/doacs-better-than-heparin-for-periop-thromboprophylaxis.htm
16 Mar 2022
Negative trials of prone positioning, antiplatelet therapy for COVID-19
Telling inpatients to lay on their stomachs did not significantly improve outcomes, one study found, while others offered some mixed results on the effects of aspirin and P2Y12 inhibitors. Additional research showed that a commonly used triage score doesn't work for COVID-19 and that hospitalists' worry about catching the virus impaired their well-being.
https://acphospitalist.acponline.org/archives/2022/03/30/free/negative-trials-of-prone-positioning-antiplatelet-therapy-for-covid-19.htm
30 Mar 2022
Risk for DVT, PE, bleeding after COVID-19, but low long-term VTE recurrence risk
One study found increased risk for deep venous thrombosis (DVT) for up to three months after COVID-19, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while another showed low rates of venous thromboembolism (VTE) recurrence in the year after infection.
https://acphospitalist.acponline.org/archives/2022/04/13/free/risk-for-dvt-pe-bleeding-seen-after-covid-19-long-term-risk-for-vte-recurrence-may-be-low.htm
13 Apr 2022
LMWH may offer best risk-benefit profile for thromboprophylaxis in medical inpatients
A meta-analysis found that an intermediate dose of low-molecular-weight heparin (LMWH) had the most favorable balance of risk and harms during hospitalization for acute illness, while unfractionated heparin and direct oral anticoagulants had the least.
https://acphospitalist.acponline.org/archives/2022/07/13/lmwh-may-offer-best-risk-benefit-profile-for-thromboprophylaxis-in-medical-inpatients.htm
13 Jul 2022
Rivaroxaban for 45 days after discharge reduced nonfatal VTEs, industry study finds
The tradeoff for the 26 fewer venous thromboembolisms (VTEs) among 10,000 recently hospitalized patients would be eight additional major bleeds, according to the new analysis of a placebo-controlled randomized trial.
https://acphospitalist.acponline.org/archives/2022/10/19/rivaroxaban-for-45-days-after-discharge-reduced-nonfatal-vtes-industry-study-finds.htm
19 Oct 2022
Aspirin noninferior to LMWH for prophylaxis after traumatic fractures, trial finds
All-cause mortality at 90 days was similar in hospitalized patients randomized to aspirin versus low-molecular-weight heparin (LMWH), and rates of deep venous thrombosis and pulmonary embolism were also low in both groups.
https://acphospitalist.acponline.org/archives/2023/01/25/aspirin-noninferior-to-lmwh-for-prophylaxis-after-traumatic-fractures-trial-finds.htm
25 Jan 2023